Advertisement

Hepatology International

, Volume 12, Issue 4, pp 348–355 | Cite as

Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4

  • Adel Abdel-MoneimEmail author
  • Alaa Aboud
  • Mohamed Abdel-Gabaar
  • Mohamed I. Zanaty
  • Mohamed Ramadan
Original Article

Abstract

Background and aim

Clinical studies evaluating the efficacy of daclatasvir (DCV) for treatment of chronic hepatitis C virus (HCV) genotype 4 (GT4) infection are scarce. This study aims to evaluate the efficacy and safety of DCV plus sofosbuvir (SOF) with or without ribavirin (RBV) for treatment of Egyptian patients infected with HCV GT4.

Methods

Between April 2016 and March of 2017, a large cohort of 946 patients with chronic HCV GT4 was enrolled for completing the treatment. Patients were classified into two groups: group 1 (easy to treat) was treated with a dual therapy of SOF/DCV daily for 12 weeks and group 2 (difficult to treat) was treated with a triple therapy of SOF/DCV/RBV daily for 12 weeks. Efficacy and safety of the treatments were estimated, and baseline characters associated with sustained virological response at 12 weeks post-treatment (SVR12) were investigated.

Results

Among the patient’s cohort, SVR12 was achieved by 94% (891/946) in the overall patients, by 95% (718/758) in the easy-to-treat group, and by 92% (173/188) in the difficult-to-treat group. The most common adverse events recorded were fatigue, headache, nausea, asthenia, and gastrointestinal troubles. No patient discontinued treatment due to severe adverse events.

Conclusion

The findings from the present study suggested that SOF/DCV (with or without RBV) regimen exhibited high effectiveness, was well tolerated in the treatment of chronic HCV GT 4, and revealed itself as a better option for patients with advanced liver disease, making the eradication of HCV a more realistic target to achieve.

Keywords

Egyptian patients Direct antiviral agents Easy-to-treat patients Difficult-to-treat patients 

Notes

Acknowledgements

The authors are thankful to the staff members of the National Treatment Centers in Beni Suef for providing the facilities used in this study.

Compliance with Ethical Standards

Ethical approval

The study was approved by each center’s institutional review board. In addition, written consent was obtained from all the patients, and the ethical committee approved the study protocol which conformed to the Egyptian National guidelines and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines (decision date: 17.2.2016).

Supplementary material

12072_2018_9868_MOESM1_ESM.doc (92 kb)
Supplementary material 1 (DOC 91 kb)

References

  1. 1.
    The polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(1):161–76.Google Scholar
  2. 2.
    Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1):S45–57.CrossRefPubMedGoogle Scholar
  3. 3.
    Alazawi W, Cunningham M, Dearden J, et al. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344–55.CrossRefPubMedGoogle Scholar
  4. 4.
    El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35:S72–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Kandeel A, Genedy M, El-Refai S, et al. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver Int. 2017;37(1):45–53.CrossRefPubMedGoogle Scholar
  6. 6.
    World Health Organization. Global hepatitis report. 2017. http://apps.who.int/iris/bitstream/10665/255016/1/9789241565455-eng.pdf?ua=1
  7. 7.
    Abdel-Moneim A, Ramadan SH. Medication of chronic hepatitis C: a review on sofosbuvir as a new antiviral drug. ASRJETS. 2015;13(1):1–23.Google Scholar
  8. 8.
    Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430–41.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Amano M, Ishikawa H. Pharmacological properties and clinical efficacy of daclatasvir (Daklinza®) and asunaprevir (Sunvepra®). Nihon Yakurigaku Zasshi. 2015;145:152–62.CrossRefPubMedGoogle Scholar
  11. 11.
    El-Khayat H, Fouad Y, Mohamed HI, et al. Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. Aliment Pharmacol Ther. 2018;47:674–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Abdel-Moneim A, Aboud A, Abdel-Gabbar M, et al. A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure. J Hepatol. 2018;68(6):217–9.  https://doi.org/10.1016/j.jhep.2018.03.010.CrossRefGoogle Scholar
  13. 13.
    Feld JJ, Jacobson IM, Sulkowski MS, et al. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int. 2017;37(1):5–18.CrossRefPubMedGoogle Scholar
  14. 14.
    EASL. Recommendations on treatment of hepatitis C. J Hepatol. 2016;66(1):153–94.Google Scholar
  15. 15.
    Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2005;43:1317–25.CrossRefGoogle Scholar
  16. 16.
    Abdel-Hamid M, El-Daly M, Molnegren V, et al. Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. J Gen Virol. 2007;88:1526–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Guedj J, Dahari H, Rong L, et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc Natl Acad Sci USA. 2013;110(10):3991–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Kishida Y. Mechanisms of virologic failure in hepatitis C and strategies for treatment failure. MOJ Immunol. 2016;4(1):00114.  https://doi.org/10.15406/moji.2016.04.00114.CrossRefGoogle Scholar
  19. 19.
    Wang C, Jia L, O’Boyle DR, et al. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother. 2014;58(9):5155–63.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Fridell RA, Qiu D, Valera L, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol. 2011;85:7312–20.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Wang C, Jia L, Huang H, et al. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother. 2012;56:1588–90.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–35.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Omar H, El Akel W, Elbaz T, et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18,378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421–31.CrossRefPubMedGoogle Scholar
  25. 25.
    Salama H, Zekri A, Medhat E, et al. Sofosbuvir plus daclatasvir with fixed versus weight adjusted dose of ribavirin for treatment of HCV, genotype 4 among Egyptian patients. EC Gastroenterol Dig Syst. 2016;1(5):143–53.Google Scholar
  26. 26.
    Babatin MA, Alghamdi AS, Albenmousa A, et al. Efficacy and safety of simeprevir or daclatasvir in combination with sofosbuvir for the treatment of hepatitis C genotype 4 infection. J Clin Gastroenterol. 2017.  https://doi.org/10.1097/MCG.0000000000000896.CrossRefGoogle Scholar
  27. 27.
    Fontaine H, Hezode C, Zoulim F, et al. Efficacy of the oral sofosbuvir-based combination in HCV genotype 4-monoinfected patients from the French observational cohort ANRS CO22 hepather. J Hepatol. 2015;62(2):S278.CrossRefGoogle Scholar
  28. 28.
    Lacombe K, Fontaine H, Dhiver C, et al. Real-world efficacy of daclatasvir and sofosbuvir, with and without ribavirin, in HIV/HCV coinfected patients with advanced liver disease in a French early access cohort. J Acquir Immune Defic Syndr. 2017;75(1):97–107.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Herzer K, Welzel TM, Spengler U, et al. Real-world experience with daclatasvir plus sofosbuvir ± ribavirin for post-liver transplant HCV recurrence and severe liver disease. Transpl Int. 2017;30:243–55.CrossRefPubMedGoogle Scholar
  30. 30.
    Coilly A, Fougerou-Leurent C, de Ledinghen V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence after liver transplantation—the CO23 ANRS CUPILT study. J Hepatol. 2016;65(4):711–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Abdel-Aziz AM, Ibrahim MA, El-Sheikh AA, et al. Effect of Sofosbuvir plus daclatasvir in hepatitis C virus genotype-4 patients: promising effect on liver fibrosis. J Clin Exp Hepatol. 2017;8(1):15–22.CrossRefPubMedGoogle Scholar
  32. 32.
    Wu LS, Jimmerson LC, Mac-Brayne CE, et al. Modeling ribavirin-induced anemia in patients with chronic hepatitis C virus. CPT Pharmacometrics Syst Pharmacol. 2016;5(2):65–73.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Abdel-Moneim A, Aboud A, Abdel-Gabbar M, et al. Retreatment efficacy of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin for hepatitis C virus genotype 4 patients. Dig Dis Sci. 2018.  https://doi.org/10.1007/s10620-018-5005-8.PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2018

Authors and Affiliations

  1. 1.Molecular Physiology Division, Faculty of ScienceBeni-Suef UniversityBeni SuefEgypt
  2. 2.Tropical Medicine Department, Faculty of MedicineBeni-Suef UniversityBeni SuefEgypt
  3. 3.Biochemistry Division, Faculty of ScienceBeni-Suef UniversityBeni SuefEgypt
  4. 4.Biotechnology Department, Faculty of Postgraduate Studies for Advanced ScienceBeni-Suef UniversityBeni SuefEgypt

Personalised recommendations